Exosome and “stem cell–like” treatments are marketed everywhere, from medical spas to overseas clinics. They’re promoted for knee pain, autoimmune disease, long COVID, skin aging, and more. If you’re researching them, here’s what the science and the FDA actually say.
What these products are
- Mesenchymal stem/stromal cells (MSCs) are cells found in bone marrow, fat, and umbilical cord tissue that can influence inflammation and tissue repair in laboratory studies.
- Exosomes are tiny vesicles cells release to carry proteins and genetic material to other cells. Exosome products contain these vesicles, not living cells.
- “Stem cell–like” or umbilical cord products is a marketing phrase. Products sold under it vary widely in what they contain, and many contain few or no living stem cells.
What the FDA says
- Very few stem cell products are FDA-approved. Approved products include cord blood–derived blood-forming cells for certain blood disorders, and in December 2024 the FDA approved the first mesenchymal stromal cell therapy, for a specific complication of bone marrow transplant in children.
- No exosome product is FDA-approved for any condition. In 2019 the FDA issued a public safety notification about exosome products after reports of serious adverse events in patients treated with unapproved products.
- Most stem cell and exosome products marketed for joint pain, autoimmune disease, or anti-aging are unapproved. The FDA has sent warning letters to clinics marketing them.
What the research shows
- Knee osteoarthritis is the most studied use. Some trials report improvements in pain, but results are inconsistent, products differ from study to study, and none has led to FDA approval for this use.
- Autoimmune disease and long COVID: research is early, mostly small or laboratory studies.
- Exosomes: human clinical evidence is very limited.
Real risks
- Serious harm has been documented. In one widely cited report in the New England Journal of Medicine (Kuriyan et al., 2017), three patients lost vision after unapproved “stem cell” eye injections.
- Infection and contamination are risks with products made outside approved manufacturing standards.
- Overseas “stem cell tourism” adds uncertainty about product content, sterility, follow-up care, and legal recourse. Medical literature includes reports of serious complications after treatment abroad.
- Cost: these treatments are typically expensive and not covered by insurance.
Questions to ask any clinic
- Is this product FDA-approved for my condition? If not, is it being given in an FDA-authorized clinical trial?
- What exactly is in the product, and how is it tested?
- What published evidence supports it for my condition?
- What are the risks, and who handles complications?
The bottom line
Cell and exosome research is promising and moving quickly. Today, though, most products marketed directly to patients are unapproved, the evidence is limited, and documented risks are real. Legitimate access to investigational cell therapies usually comes through registered clinical trials, which you can search at ClinicalTrials.gov.
Frequently asked questions
Are exosome treatments FDA-approved?
No. No exosome product is FDA-approved for any condition.
Is umbilical cord “stem cell” therapy safe?
Products vary widely and most marketed ones are unapproved. Safety depends on what’s actually in the product and how it’s made, which is often unclear.
Is it safer to get stem cell treatment overseas?
Treatment abroad adds uncertainty about product quality, sterility, and follow-up care.
Where can I find legitimate stem cell research?
Search ClinicalTrials.gov for registered trials in your condition.
This article is an educational review of published research and regulatory information. It is not a recommendation for any treatment and is not a substitute for individual evaluation. From Venturis Clinic in Oklahoma City.
By Alvin Philipose, DC, ICCP
Sources
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. 2019.
- U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products.
- Kuriyan AE, et al. Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine. 2017;376:1047–1053.
